鈉–葡萄糖協(xié)同轉(zhuǎn)運(yùn)蛋白2（SGLT2）抑制劑是近年來(lái)降糖藥研究的新熱點(diǎn)，通過(guò)抑制腎小管上皮細(xì)胞內(nèi)的主要血糖轉(zhuǎn)運(yùn)蛋白SGLT2降低腎內(nèi)濾過(guò)葡萄糖的重吸收，導(dǎo)致糖尿，從而降低血清內(nèi)葡萄糖。新型SGLT2抑制劑empagliflozin具有良好的降糖效果，單次給藥就能顯著增加尿中排糖，多次給藥后劑量相關(guān)性地降低FPG、HbA1c和體質(zhì)量，作為補(bǔ)充藥物治療還能顯著降低血壓，目前正在進(jìn)行Ⅲ期臨床試驗(yàn)。

Sodium-glucose linked transporter 2 (SGLT2) inhibitor is a hot target for hypoglycemic agents in recent years, by inhibiting the main glucose transporter SGLT2 in renal tubular epithelial cells to reduce renal glucose reabsorption filtration, resulting in urine glucose excretion and reducing serum glucose concentration. New SGLT2 inhibitor empagliflozin has good hypoglycemic effects, single dosing can significantly increase urine glucose excretion, after multiple dosing, FPG, HbA1c, and body weight were decreased in a dose-dependent manner. As a supplementary drug, empagliflozin significantly reduces blood pressure and now is undergoing phase III clinical trials.